One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
PainReform Ltd. logo
PainReform Ltd. PRFX
$ 0.47 -25.4%
report update icon

Quarterly report 2024-Q4
added 11-13-2026

PainReform Ltd. Income Statement 2025-2011 | PRFX

Annual Income Statement PainReform Ltd.

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

1.72 M 289 K 155 K 675 K 1.01 M 21.1 M 1.7 M 2.81 M - - - - - - -

Shares

648 K 138 K 76 K 139 K 1 M 3.24 M 577 K 577 K - - - - - - -

Historical Prices

2.65 2.09 2.04 4.87 1.01 6.49 - - - - - - - - -

Net Income

-5.02 M -14.6 M -9.34 M -8.79 M -7.25 M -4.05 M -1.28 M -828 K - - - - - - -

Revenue

17 K - - - - - - - - - - - - - -

Cost of Revenue

70 K - - - - - - - - - - - - - -

Gross Profit

-53 K - - - - - - - - - - - - - -

Operating Income

-5.12 M -14.7 M -9.58 M -8.87 M -7.21 M -1.67 M -689 K -500 K - - - - - - -

EBITDA

-5.11 M -14.7 M -9.57 M -8.85 M -7.2 M -1.67 M -688 K -500 K - - - - - - -

Operating Expenses

5.07 M 14.7 M 9.58 M - - - 689 K 500 K - - - - - - -

General and Administrative Expenses

55 K 124 K 147 K 172 K 105 K 19 K 43 K 25 K - - - - - - -

All numbers in USD currency

Quarterly Income Statement PainReform Ltd.

2025-Q4 2025-Q2 2024-Q4 2024-Q2 2023-Q4 2023-Q2 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

648 K 2.12 M 138 K 4.11 M 76 K 1.09 M - - - - 10.5 M - 10.1 M - 8.76 M - 577 K - 577 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-5.02 M -2.32 M -14.6 M -12.8 M -9.34 M -4.49 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

17 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

70 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

-53 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-5.12 M -2.37 M -14.7 M -12.9 M -9.58 M -4.67 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

-5.11 M -2.36 M -14.7 M -12.9 M -9.57 M -4.66 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

5.07 M - 14.7 M - 9.58 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

55 K 1.92 M 124 K 1.5 M 147 K 1.97 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company PainReform Ltd. (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Shattuck Labs Shattuck Labs
STTK
$ 4.49 -1.43 % $ 312 M usaUSA
Silence Therapeutics plc Silence Therapeutics plc
SLN
$ 19.81 0.08 % $ 2.81 B britainBritain
Soligenix Soligenix
SNGX
$ 0.22 -8.25 % $ 1.14 M usaUSA
Sanofi Sanofi
SNY
$ 46.51 0.97 % $ 56.8 B franceFrance
Spruce Biosciences Spruce Biosciences
SPRB
$ 38.02 -6.11 % $ 29.1 M usaUSA
Spero Therapeutics Spero Therapeutics
SPRO
$ 0.74 -10.95 % $ 41.5 M usaUSA
Sarepta Therapeutics Sarepta Therapeutics
SRPT
$ 13.34 -5.86 % $ 1.34 B usaUSA
Savara Savara
SVRA
$ 4.28 -17.95 % $ 952 M usaUSA
Teligent, Inc. Teligent, Inc.
TLGT
- -13.85 % $ 16.1 M usaUSA
Viela Bio, Inc. Viela Bio, Inc.
VIE
- - $ 2.91 B usaUSA
Sutro Biopharma Sutro Biopharma
STRO
$ 8.6 -1.38 % $ 73.1 M usaUSA
Tarsus Pharmaceuticals Tarsus Pharmaceuticals
TARS
$ 72.94 -6.09 % $ 3.05 B usaUSA
Supernus Pharmaceuticals Supernus Pharmaceuticals
SUPN
$ 36.28 1.88 % $ 2.05 B usaUSA
TG Therapeutics TG Therapeutics
TGTX
$ 63.39 -2.3 % $ 9.15 B usaUSA
Aphria Inc. Aphria Inc.
APHA
- -0.45 % $ 4.87 B canadaCanada
Viridian Therapeutics Viridian Therapeutics
VRDN
$ 29.91 -4.87 % $ 3.05 B usaUSA
Trevi Therapeutics Trevi Therapeutics
TRVI
$ 13.35 -2.73 % $ 1.8 B usaUSA
Aerpio Pharmaceuticals, Inc. Aerpio Pharmaceuticals, Inc.
ARPO
- -0.90 % $ 104 M usaUSA
Chiasma, Inc. Chiasma, Inc.
CHMA
- -6.00 % $ 238 M usaUSA
vTv Therapeutics vTv Therapeutics
VTVT
$ 16.0 -2.2 % $ 64.2 M usaUSA
Adamas Pharmaceuticals, Inc. Adamas Pharmaceuticals, Inc.
ADMS
- - $ 376 M usaUSA
Cellect Biotechnology Ltd. Cellect Biotechnology Ltd.
APOP
- 0.38 % $ 12.9 M israelIsrael
Xenon Pharmaceuticals Xenon Pharmaceuticals
XENE
$ 36.89 -1.78 % $ 2.92 B canadaCanada
Xeris Pharmaceuticals Xeris Pharmaceuticals
XERS
$ 16.95 2.02 % $ 2.72 B usaUSA
AzurRx BioPharma, Inc. AzurRx BioPharma, Inc.
AZRX
- 2.07 % $ 34.4 M usaUSA
X4 Pharmaceuticals X4 Pharmaceuticals
XFOR
$ 3.01 1.69 % $ 127 M usaUSA
Cerecor Inc. Cerecor Inc.
CERC
- -1.68 % $ 283 M usaUSA
Constellation Pharmaceuticals, Inc. Constellation Pharmaceuticals, Inc.
CNST
- - $ 1.63 B usaUSA
Auris Medical Holding Ltd. Auris Medical Holding Ltd.
EARS
- -1.77 % $ 39.2 M bermudaBermuda
Dicerna Pharmaceuticals, Inc. Dicerna Pharmaceuticals, Inc.
DRNA
- 0.34 % $ 2.98 B usaUSA
ERYTECH Pharma S.A. ERYTECH Pharma S.A.
ERYP
- 1.3 % $ 27.7 M franceFrance
GW Pharmaceuticals plc GW Pharmaceuticals plc
GWPH
- - $ 6.81 B britainBritain
22nd Century Group 22nd Century Group
XXII
$ 0.32 -19.83 % $ 58.9 K usaUSA
Kadmon Holdings, Inc. Kadmon Holdings, Inc.
KDMN
- - $ 1.7 B usaUSA
Liminal BioSciences Liminal BioSciences
LMNL
- - $ 256 M canadaCanada
argenx SE argenx SE
ARGX
$ 926.42 -1.66 % $ 56.8 B niderlandNiderland
Tonix Pharmaceuticals Holding Corp. Tonix Pharmaceuticals Holding Corp.
TNXP
$ 2.33 -7.25 % $ 19.8 M usaUSA
Zai Lab Limited Zai Lab Limited
ZLAB
$ 21.01 -4.16 % $ 23 B chinaChina
Neos Therapeutics, Inc. Neos Therapeutics, Inc.
NEOS
- -2.54 % $ 57.2 M usaUSA
Zentalis Pharmaceuticals Zentalis Pharmaceuticals
ZNTL
$ 1.37 0.74 % $ 98.5 M usaUSA
Zoetis Zoetis
ZTS
$ 78.81 -2.47 % $ 34.9 B usaUSA
Odonate Therapeutics, Inc. Odonate Therapeutics, Inc.
ODT
- -3.18 % $ 58.5 M usaUSA
Orphazyme A/S Orphazyme A/S
ORPH
- -2.25 % $ 31.3 M danmarkDanmark
Osmotica Pharmaceuticals plc Osmotica Pharmaceuticals plc
OSMT
- -10.74 % $ 89.9 M usaUSA
Pandion Therapeutics, Inc. Pandion Therapeutics, Inc.
PAND
- - $ 1.77 B usaUSA
Xenetic Biosciences Xenetic Biosciences
XBIO
$ 1.47 -4.55 % $ 2.5 M usaUSA
Translate Bio, Inc. Translate Bio, Inc.
TBIO
- - $ 2.81 B usaUSA
Trillium Therapeutics Inc. Trillium Therapeutics Inc.
TRIL
- - $ 1.94 B canadaCanada
Urovant Sciences Ltd. Urovant Sciences Ltd.
UROV
- - $ 532 M britainBritain
Acceleron Pharma Inc. Acceleron Pharma Inc.
XLRN
- - $ 10.9 B usaUSA